Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goetz, C. G.
Right arrow Articles by Stebbins, G. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goetz, C. G.
Right arrow Articles by Stebbins, G. T.
NEUROLOGY 1995;45:669-671
© 1995 American Academy of Neurology

Mortality and hallucinations in nursing home patients with advanced Parkinson's disease

Christopher G. Goetz, MD and Glenn T. Stebbins, PhD

Article abstract-We monitored 11 patients with advanced Parkinson's disease (PD) who entered nursing homes over a 5-year period and assessed chronicity of nursing home care, mortality, and hallucinatory status. Two years after the original study's close, none of these patients had ever been discharged from the nursing homes and all were dead. The mortality rate among the nursing home patients was significantly greater than that in 22 community-dwelling subjects with PD who were matched for age, gender, and disease duration. Hallucinatory status was generally stable; 82% of patients had the same hallucinatory status (presence or absence) at the two assessments. Four subjects from the original community-dwelling control group entered nursing homes during the follow-up period. Whereas motor and intellectual impairment scores were similar between these patients and the remaining 18 in the community, the presence of hallucinations was significantly greater among patients transferred to nursing homes. The study demonstrates the permanency of nursing home placement in advanced PD and the high mortality associated with such placement. It also documents the chronicity of hallucinatory behavior in these patients with advanced PD and reinforces our previously reported observations on the relationship between hallucinations and placement in chronic-care facilities.

NEUROLOGY 1995;45: 669-671




This article has been cited by other articles:


Home page
Arch NeurolHome page
R. Y. Lo, C. M. Tanner, K. B. Albers, A. D. Leimpeter, R. D. Fross, A. L. Bernstein, V. McGuire, C. P. Quesenberry, L. M. Nelson, and S. K. Van Den Eeden
Clinical Features in Early Parkinson Disease and Survival
Arch Neurol, November 1, 2009; 66(11): 1353 - 1358.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
N. K. Archibald, M. P. Clarke, U. P. Mosimann, and D. J. Burn
The retina in Parkinson's disease
Brain, May 1, 2009; 132(5): 1128 - 1145.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
K. M. Biglan, R. G. Holloway Jr, M. P. McDermott, I. H. Richard, and The Parkinson Study Group CALM-PD Investigators
Risk factors for somnolence, edema, and hallucinations in early Parkinson disease
Neurology, July 10, 2007; 69(2): 187 - 195.
[Abstract] [Full Text] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
D Aarsland, K Bronnick, U Ehrt, P P De Deyn, S Tekin, M Emre, and J L Cummings
Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress
J. Neurol. Neurosurg. Psychiatry, January 1, 2007; 78(1): 36 - 42.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
C. G. Goetz, J. Wuu, L. M. Curgian, and S. Leurgans
Hallucinations and sleep disorders in PD: Six-year prospective longitudinal study
Neurology, January 11, 2005; 64(1): 81 - 86.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
G. T. Stebbins, C. G. Goetz, M. C. Carrillo, K. J. Bangen, D. A. Turner, G. H. Glover, and J. D.E. Gabrieli
Altered cortical visual processing in PD with hallucinations: An fMRI study
Neurology, October 26, 2004; 63(8): 1409 - 1416.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
J. Kulisevsky and E. Roldan
Hallucinations and sleep disturbances in Parkinson's disease
Neurology, October 26, 2004; 63(8_suppl_3): S28 - S30.
[Abstract] [Full Text]


Home page
J Geriatr Psychiatry NeurolHome page
D. P. Wint, M. S. Okun, and H. H. Fernandez
Psychosis in Parkinson's Disease
J Geriatr Psychiatry Neurol, September 1, 2004; 17(3): 127 - 136.
[Abstract] [PDF]


Home page
Arch NeurolHome page
J. G. Goldman, C. G. Goetz, E. Berry-Kravis, S. Leurgans, and L. Zhou
Genetic Polymorphisms in Parkinson Disease Subjects With and Without Hallucinations: An Analysis of the Cholecystokinin System
Arch Neurol, August 1, 2004; 61(8): 1280 - 1284.
[Abstract] [Full Text] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
P Pollak, F Tison, O Rascol, A Destee, J J Pere, J M Senard, F Durif, and I Bourdeix
Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up
J. Neurol. Neurosurg. Psychiatry, May 1, 2004; 75(5): 689 - 695.
[Abstract] [Full Text] [PDF]


Home page
J. Neuropsychiatry Clin. Neurosi.Home page
M. S. Ismail and I. H. Richard
A Reality Test: How Well Do We Understand Psychosis in Parkinson's Disease?
J Neuropsychiatry Clin Neurosci, February 1, 2004; 16(1): 8 - 18.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
S. A. Factor, P. J. Feustel, J. H. Friedman, C. L. Comella, C. G. Goetz, R. Kurlan, M. Parsa, R. Pfeiffer, and the Parkinson Study Group
Longitudinal outcome of Parkinson's disease patients with psychosis
Neurology, June 10, 2003; 60(11): 1756 - 1761.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
V.L. Wheelock, T. Tempkin, K. Marder, M. Nance, R.H. Myers, H. Zhao, E. Kayson, C. Orme, and I. Shoulson
Predictors of nursing home placement in Huntington disease
Neurology, March 25, 2003; 60(6): 998 - 1001.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
G. Levy, M.-X. Tang, E.D. Louis, L.J. Cote, B. Alfaro, H. Mejia, Y. Stern, and K. Marder
The association of incident dementia with mortality in PD
Neurology, December 10, 2002; 59(11): 1708 - 1713.
[Abstract] [Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
S. A. Parashos, D. M. Maraganore, P. C. O'Brien, and W. A. Rocca
Medical Services Utilization and Prognosis in Parkinson Disease: A Population-Based Study
Mayo Clin. Proc., September 1, 2002; 77(9): 918 - 925.
[Abstract] [PDF]


Home page
NeurologyHome page
C. G. Goetz, S. Leurgans, E. J. Pappert, R. Raman, and A. B. Stemer
Prospective longitudinal assessment of hallucinations in Parkinson's disease
Neurology, December 11, 2001; 57(11): 2078 - 2082.
[Abstract] [Full Text] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
S Holroyd, L Currie, and G F Wooten
Prospective study of hallucinations and delusions in Parkinson's disease
J. Neurol. Neurosurg. Psychiatry, June 1, 2001; 70(6): 734 - 738.
[Abstract] [Full Text] [PDF]


Home page
Arch NeurolHome page
C. G. Goetz, P. F. Burke, S. Leurgans, E. Berry-Kravis, L. M. Blasucci, R. Raman, and L. Zhou
Genetic Variation Analysis in Parkinson Disease Patients With and Without Hallucinations: Case-Control Study
Arch Neurol, February 1, 2001; 58(2): 209 - 213.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
C. M. Tanner
Dopamine Agonists in Early Therapy for Parkinson Disease: Promise and Problems
JAMA, October 18, 2000; 284(15): 1971 - 1973.
[Full Text] [PDF]


Home page
NeurologyHome page
C. G. Goetz, L. M. Blasucci, S. Leurgans, and E. J. Pappert
Olanzapine and clozapine: Comparative effects on motor function in hallucinating PD patients
Neurology, September 26, 2000; 55(6): 789 - 794.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
G. Fenelon, F. Mahieux, R. Huon, and M. Ziegler
Hallucinations in Parkinson's disease: Prevalence, phenomenology and risk factors
Brain, April 1, 2000; 123(4): 733 - 745.
[Abstract] [Full Text] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
M. A Hely, J. G L Morris, R. Traficante, W. G J Reid, D. J O'Sullivan, and P. M Williamson
The Sydney multicentre study of Parkinson's disease: progression and mortality at 10 years
J. Neurol. Neurosurg. Psychiatry, September 1, 1999; 67(3): 300 - 307.
[Abstract] [Full Text]


Home page
NEJMHome page
The Parkinson Study Group
Low-Dose Clozapine for the Treatment of Drug-Induced Psychosis in Parkinson's Disease
N. Engl. J. Med., March 11, 1999; 340(10): 757 - 763.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
J. L. Cummings
Managing Psychosis in Patients with Parkinson's Disease
N. Engl. J. Med., March 11, 1999; 340(10): 801 - 803.
[Full Text]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
I. Litvan, J. L Cummings, and M. Mega
Neuropsychiatric features of corticobasal degeneration
J. Neurol. Neurosurg. Psychiatry, November 1, 1998; 65(5): 717 - 721.
[Abstract] [Full Text]


Home page
NEJMHome page
A. E. Lang and A. M. Lozano
Parkinson's Disease- Second of Two Parts
N. Engl. J. Med., October 15, 1998; 339(16): 1130 - 1143.
[Full Text] [PDF]


Home page
Arch NeurolHome page
J. R. Sanchez-Ramos, R. Ortoll, and G. W. Paulson
Visual Hallucinations Associated With Parkinson Disease
Arch Neurol, December 1, 1996; 53(12): 1265 - 1268.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by AAN Enterprises, Inc.